Table 1.
Antibacterial and antifungal activities of the synthesized compounds (6a–g) and 10.
| Sample/Tested Organism | 6a | 6b | 6c | 6d | 6e | 6f | 6g | 10 | Standard | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fungi | Itraconazole | Clotrimazole | ||||||||
| Aspergillus fumigatus(AF) | 11.7 ± 0.2 | 15.4 ± 0.09 | 13.3 ± 0.2 | 16.4 ± 0.3 | 9.3 ± 0.2 | 17.4 ± 0.08 | 12.2 ± 0.09 | 14.3 ± 0.2 | 28.5 ± 0.05 | 26 ± 0.1 |
| Geotrichum candidum(GC) | 13.5 ± 0.1 | 14.9 ± 0.05 | 14.4 ± 0.1 | 18.1 ± 0.08 | 11.4 ± 0.1 | 18.3 ± 0.3 | 14.4 ± 0.03 | 16.7 ± 0.08 | 27.1 ± 0.06 | 23.1 ± 0.03 |
| Candida albicans(CA) | 10.4 ± 0.08 | NA | 10.2 ± 0.09 | 13.7 ± 0.05 | NA | NA | NA | 11.9 ± 0.1 | 26.1 ± 0.02 | 18.3 ± 0.01 |
| Syncephalastrum racemosum(SR) | NA | 12.1 ± 0.08 | NA | NA | 8.2 ± 0.09 | 14.2 ± 0.08 | 9.2 ± 0.08 | NA | 22.3 ± 0.09 | 20.5 ± 0.02 |
| Gram Positive Bacteria | Penicillin G | Streptomycin | ||||||||
| Staphylococcus aureus(SA) | 11.2 ± 0.1 | 17.9 ± 0.05 | 11.3 ± 0.05 | 15.4 ± 0.5 | 9.4 ± 0.05 | 18.9 ± 0.01 | 13.8 ± 0.1 | 13.4 ± 0.3 | 29.4 ± 0.08 | 25.1 ± 0.08 |
| Bacillis subtilis(BS) | 13.7 ± 0.07 | 16.1 ± 0.01 | 9.0 ± 0.08 | 18.4 ± 0.1 | 10.6 ± 0.08 | 20.9 ± 0.03 | 16.6 ± 0.03 | 14.7 ± 0.09 | 32.5 ± 0.06 | 29.1 ± 0.04 |
| Gram Negative Bacteria | Penicillin G | Streptomycin | ||||||||
| Pseudomonas aeruginosa(PA) | NA | 10.1 ± 0.01 | NA | NA | NA | 12.1 ± 0.01 | NA | NA | 28.3 ± 0.05 | 24.3 ± 0.08 |
| Escherichia coli(EC) | 8.3 ± 0.09 | 14.5 ± 0.2 | 10.1 ± 0.07 | 13.7 ± 0.05 | 7.4 ± 0.07 | 15.2 ± 0.5 | 9.5 ± 0.2 | 10.9 ± 0.2 | 33.5 ± 0.7 | 25.6 ± 0.04 |
NA: No activity, data are expressed in the form of mean ± SD. Mean zone of inhibition in mm ± Standard deviation beyond well diameter (6 mm) produced on a range of environmental and clinically pathogenic microorganisms using (5 mg/mL) concentration of tested samples.